Scholarlink

Background <p>Immune checkpoint inhibitors (ICIs) have recently emerged as a promising strategy for the treatment of pleural mesothelioma (PM).</p> Methods <p>This retrospective study evaluated treatment efficacy and safety in Japanese patients with PM treated with nivolumab and ipilimumab (N + I group: 41 patients) as first-line therapy and nivolumab monotherapy (N group: 33 patients) as second- or later-line treatment.</p> Results <p>The median overall survival (OS) and progression-free survival (PFS) were not reached and 10.4&#xa0;months in the N + I group, and 8.6&#xa0;months and 3.5&#xa0;months in the N group, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 68.3% of the N + I group and 72.7% of the N group, with grade 3–4 TRAEs in 19.5% and 12.1% of patients, respectively. Patients with an ECOG PS&#xa0;0–1 had significantly better OS and PFS in both treatment groups (p &lt; 0.001). In the N + I group, OS was significantly better in patients with TRAEs (p = 0.020) and in those with the epithelioid subtype (p = 0.047), although PFS was not significantly different (p = 0.138 and p = 0.154, respectively). In the N group, both OS (p = 0.007) and PFS (p = 0.048) were significantly longer in patients with TRAEs.</p> Conclusion <p>This study provides valuable real-world clinical evidence of the efficacy and safety of nivolumab plus ipilimumab and nivolumab monotherapy in Japanese patients with PM. These results support the use of ICIs as a viable treatment option for advanced or relapsed disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data

  • 期刊论文

  • 发表日期：

    2025年2月12日

查看全文
  • Masatoshi Kanayama,
  • Takehiko Manabe,
  • Katsuma Yoshimatsu,
  • Rintaro Oyama,
  • Hiroki Matsumiya,
  • Masataka Mori,
  • Masaru Takenaka,
  • Koji Kuroda,
  • Fumihiro Tanaka

摘要

Background

Immune checkpoint inhibitors (ICIs) have recently emerged as a promising strategy for the treatment of pleural mesothelioma (PM).

Methods

This retrospective study evaluated treatment efficacy and safety in Japanese patients with PM treated with nivolumab and ipilimumab (N + I group: 41 patients) as first-line therapy and nivolumab monotherapy (N group: 33 patients) as second- or later-line treatment.

Results

The median overall survival (OS) and progression-free survival (PFS) were not reached and 10.4 months in the N + I group, and 8.6 months and 3.5 months in the N group, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 68.3% of the N + I group and 72.7% of the N group, with grade 3–4 TRAEs in 19.5% and 12.1% of patients, respectively. Patients with an ECOG PS 0–1 had significantly better OS and PFS in both treatment groups (p < 0.001). In the N + I group, OS was significantly better in patients with TRAEs (p = 0.020) and in those with the epithelioid subtype (p = 0.047), although PFS was not significantly different (p = 0.138 and p = 0.154, respectively). In the N group, both OS (p = 0.007) and PFS (p = 0.048) were significantly longer in patients with TRAEs.

Conclusion

This study provides valuable real-world clinical evidence of the efficacy and safety of nivolumab plus ipilimumab and nivolumab monotherapy in Japanese patients with PM. These results support the use of ICIs as a viable treatment option for advanced or relapsed disease.